Microchip-based human serum atherogenic lipoprotein profile analysis

Wang, Hua; Zhang, Wei; Wan, Jun; Liu, Weiwei; Yu, Bo; Jin, Qinghui; Guan, Ming

doi:10.1016/j.ab.2014.08.031

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microfluidic chip technology, 21,[35][36][37][38][39] similar to other new techniques in clinical lipid measurements such as vertical auto profile (VAP), 40 nuclear magnetic resonance spectroscopy (NMRS), 41,42 electrospray differential mobility analysis (ES-DMA), 43 and liquid chromatography-mass spectrometry (LC-MS), 44 is becoming increasingly mature. Previous studies have shown that microfluidic chip technology has since been used in T2DM, 21,37 obesity, 27 atherosclerosis 38 and polycystic ovarian syndrome. 36 The clinical application of these new techniques has significantly promoted the use of lipoprotein subtypes in the risk stratification of cardiovascular diseases.…”

Section: Discussionmentioning

confidence: 99%

The Association of HDL2b with Metabolic Syndrome Among Normal HDL-C Populations in Southern China

Chen,

Wu,

Feng

et al. 2024

DMSO

View full text Add to dashboard Cite

Background The annual prevalence of metabolic syndrome (MetS) is increasing. Therefore, early screening and recognition of MetS are critical. This study aimed to evaluate the association between high-density lipoprotein (HDL) subclasses and MetS and to examine whether they could serve as early indicators in a Chinese community-based population with normal high-density lipoprotein cholesterol (HDL-C) levels. Methods We used microfluidic chip technology to measure HDL subclasses in 463 people with normal HDL levels in 2018. We assessed how HDL subclasses correlated with and predicted insulin resistance (IR) and metabolic syndrome (MetS), evaluated by homeostatic model insulin resistance index (HOMA-IR) and the 2009 International Diabetes Federation (IDF), the American Heart Association (AHA), and the National Heart, Lung, and Blood Institute (NHLBI) criteria, respectively. We used correlation tests and ROC curves for the analysis. Results The results indicate that there was a negative association between HDL2b% and the risk of IR and MetS in both sexes. Subjects in the highest quartile of HDL2b% had a significantly lower prevalence of IR and MetS than those in the lowest quartile (P<0.01). Correlation analysis between HDL2b% and metabolic risk factors showed that HDL2b% had a stronger association with these factors than HDL-C did in both sexes. ROC curve analysis also showed that HDL2b% had significant diagnostic value for IR and MetS compared to other lipid indicators. Conclusion This study showed that MetS alters the distribution of HDL subclasses even when HDL-C levels are within the normal range. HDL-2b% has better diagnostic value for IR and MetS than HDL-C alone and may be a useful marker for early screening.

show abstract

Section: Discussionmentioning

confidence: 99%

The Association of HDL2b with Metabolic Syndrome Among Normal HDL-C Populations in Southern China

Chen,

Wu,

Feng

et al. 2024

DMSO

View full text Add to dashboard Cite

show abstract

“…Acute myocardial infarction [122,123], coronary artery disease [124][125][126][127][128], and hypertension [129] were investigated.…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

A decade of microchip electrophoresis for clinical diagnostics – A review of 2008–2017

Wuethrich

Quirino

2019

Analytica Chimica Acta

View full text Add to dashboard Cite

A core element in clinical diagnostics is the data interpretation obtained through the analysis of patient samples. To obtain relevant and reliable information, a methodological approach of sample preparation, separation, and detection is required. Traditionally, these steps are performed independently and stepwise. Microchip capillary electrophoresis (MCE) can provide rapid and high-resolution separation with the capability to integrate a streamlined and complete diagnostic workflow suitable for the point-of-care setting. Whilst standard clinical diagnostics methods normally require hours to days to retrieve specific patient data, MCE can reduce the time to minutes, hastening the delivery of treatment options for the patients. This review covers the advances in MCE for disease detection from 2008 to 2017. Miniaturised diagnostic approaches that required an electrophoretic separation step prior to the detection of the biological samples are reviewed. In the two main sections, the discussion is focused on the technical setup used to suit MCE for disease detection and on the strategies that have been applied to study various diseases. Throughout these discussions MCE is compared to other techniques to create context of the potential and challenges of MCE. A comprehensive table categorised based on the studied disease using MCE is provided. We also comment on future challenges that remain to be addressed.

show abstract

“…Of note is the report by Wang et al. who used ME to analyze lipoprotein profiles in atherogenic patients and normal controls. The addition of gold nanoparticles to the sample followed by labeling with NBD C6‐ceramide greatly improved quantification of the individual lipoproteins.…”

Section: Applications In Different Clinical Fieldsmentioning

confidence: 99%

Recent advances in CE and microchip‐CE in clinical applications: 2014 to mid‐2017

Phillips

2017

Electrophoresis

View full text Add to dashboard Cite

Recent advances in CE and microchip-CE in clinical applications: 2014 to mid-2017CE and microchip CE (ME) are powerful tools for the analysis of a number of different analytes and have been applied to a variety of clinical fields and human samples. This review will present an overview of the most recent applications of these techniques to different areas of clinical medicine during the period of 2014 to mid-2017. CE and ME have been applied to clinical chemistry, drug detection and monitoring, hematology, infectious diseases, oncology, endocrinology, neonatology, nephrology, and genetic screening. Samples examined range from serum, plasma, and urine to lest utilized materials such as tears, cerebral spinal fluid, sweat, saliva, condensed breath, single cells, and biopsy tissue. Examples of clinical applications will be given along with the various detection systems employed.

show abstract

Microchip-based human serum atherogenic lipoprotein profile analysis

Cited by 6 publications

References 29 publications

The Association of HDL2b with Metabolic Syndrome Among Normal HDL-C Populations in Southern China

The Association of HDL2b with Metabolic Syndrome Among Normal HDL-C Populations in Southern China

A decade of microchip electrophoresis for clinical diagnostics – A review of 2008–2017

Recent advances in CE and microchip‐CE in clinical applications: 2014 to mid‐2017

Contact Info

Product

Resources

About